{"id":"NCT01491607","sponsor":"Emergent BioSolutions","briefTitle":"Immunogenicity and Safety Study of a Three-Dose BioThrax® Regimen for Post-Exposure Prophylaxis in Healthy Adults","officialTitle":"Immunogenicity and Safety Study of a Three-Dose BioThrax® Regimen for Post-Exposure Prophylaxis in Healthy Adults","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2011-11","primaryCompletion":"2012-05","completion":"2012-05","firstPosted":"2011-12-14","resultsPosted":"2013-11-28","lastUpdate":"2024-04-09"},"enrollment":200,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Anthrax"],"interventions":[{"type":"BIOLOGICAL","name":"BioThrax","otherNames":["Anthrax Vaccine Adsorbed (AVA)"]}],"arms":[{"label":"BioThrax (0.5 mL, on days 0, 14, and 28)","type":"EXPERIMENTAL"}],"summary":"The purpose of this Phase 3 clinical trial is to evaluate the immunogenicity and safety of BioThrax anthrax vaccine in healthy adults following 3 doses of BioThrax. Results of this study will be used to support a post-exposure prophylaxis (PEP) indication for BioThrax.\n\nThis study will be conducted in the United States (U.S.), in 200 healthy male and female volunteer subjects ages 18 to 65 years.\n\nThe duration of study participation for each individual subject will be approximately 128 days (4.25 months), including a screening period of approximately 28 days followed by 100 days on study.","primaryOutcome":{"measure":"Percentage of Subjects Achieving a TNA Response of a Predefined Threshold Value at Day 63 (5 Weeks Following the Third Vaccination on Day 28).","timeFrame":"Day 63 +/- 2 days","effectByArm":[{"arm":"BioThrax","deltaMin":71.2,"sd":null},{"arm":"BioThrax - Male","deltaMin":68.5,"sd":null},{"arm":"BioThrax - Female","deltaMin":73.9,"sd":null},{"arm":"BioThrax - ≤ 30 Years of Age","deltaMin":76.7,"sd":null},{"arm":"BioThrax- > 30 Years of Age","deltaMin":66,"sd":null},{"arm":"BioThrax - Caucasian","deltaMin":73.7,"sd":null},{"arm":"BioThrax - Non-Caucasian","deltaMin":57.1,"sd":null},{"arm":"BioThrax - Site 01","deltaMin":91.1,"sd":null},{"arm":"BioThrax - Site 02","deltaMin":67.6,"sd":null},{"arm":"BioThrax - Site 03","deltaMin":69.6,"sd":null},{"arm":"BioThrax - Site 04","deltaMin":57.1,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":true,"inclusionCount":6,"exclusionCount":11},"locations":{"siteCount":4,"countries":["United States"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":2,"n":200},"commonTop":["Upper respiratory tract infection","Headache","Fatigue","Myalgia","Oropharyngeal pain"]}}